Free Trial
→ My public warning after 55 years of watching the markets (From Weiss Ratings) (Ad)tc pixel Free SLN Stock Alerts

Silence Therapeutics (SLN) Financials

Silence Therapeutics logo
$19.83 +0.03 (+0.15%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$19.84 +0.01 (+0.03%)
As of 11/13/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Silence Therapeutics

Annual Income Statements for Silence Therapeutics

This table shows Silence Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -23 -26 -44 -53 -50 -54 -45 -89
Consolidated Net Income / (Loss)		 -23 -26 -44 -53 -50 -54 -45 -89
Net Income / (Loss) Continuing Operations		 -23 -26 -44 -53 -50 -54 -45 -89
Total Pre-Tax Income 		-26 -30 -49 -62 -50 -53 -44 -89
Total Operating Income		 -26 -30 -49 -62 -61 -64 -63 -91
Total Gross Profit		 0.00 0.32 2.34 6.69 8.19 19 31 0.34
Total Revenue		 0.00 0.32 7.48 17 22 32 43 0.56
Operating Revenue		 0.00 0.32 7.48 17 22 32 43 0.56
Total Cost of Revenue		 0.00 0.00 5.14 10 13 13 12 0.22
Operating Cost of Revenue		 0.00 0.00 5.14 10 13 13 12 0.22
Total Operating Expenses		 26 30 51 69 69 83 95 91
Selling, General & Admin Expense		 14 13 19 27 26 26 27 22
Research & Development Expense		 12 18 28 42 44 57 68 68
Restructuring Charge		 - - - - - - 0.00 1.32
Total Other Income / (Expense), net		 0.05 -0.18 -0.26 -0.06 11 11 19 2.48
Interest Expense		 0.00 0.22 0.44 0.07 -9.82 -12 -14 -7.46
Other Income / (Expense), net		 - - - - 1.57 -0.84 5.12 -4.99
Income Tax Expense		 -2.69 -4.36 -4.77 -8.70 0.69 0.96 0.85 0.01
Basic Earnings per Share		 ($0.26) - - - ($0.52) ($0.49) ($0.33) ($0.63)
Weighted Average Basic Shares Outstanding		 - - 83.31M 89.78M 96.58M 111.28M 138.75M 141.69M
Diluted Earnings per Share		 ($0.26) - - - ($0.52) ($0.49) ($0.33) ($0.63)
Weighted Average Diluted Shares Outstanding		 - - 83.31M 89.78M 96.58M 111.28M 138.75M 141.69M
Weighted Average Basic & Diluted Shares Outstanding		 - - 83.31M 89.78M 107.81M 118.85M 141.67M 141.70M

Quarterly Income Statements for Silence Therapeutics

This table shows Silence Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -2.31 -20 -36 12 -29 -27 -21 -12 -15 -12 -12
Consolidated Net Income / (Loss)		 -2.31 -20 -36 12 -29 -27 -21 -12 -15 -12 -12
Net Income / (Loss) Continuing Operations		 -2.31 -20 -36 12 -29 -27 -21 -12 -15 -12 -12
Total Pre-Tax Income 		-2.07 -20 -35 13 -29 -27 -21 -12 -15 -12 -12
Total Operating Income		 -5.58 -23 -30 -4.35 -28 -24 -26 -12 -16 -14 -14
Total Gross Profit		 13 -2.58 -2.14 23 0.09 0.14 0.10 0.02 0.41 0.00 0.00
Total Revenue		 16 0.76 1.50 25 0.14 0.22 0.16 0.03 0.42 0.00 0.00
Operating Revenue		 16 0.76 1.50 25 0.14 0.22 0.16 0.03 0.42 0.00 0.00
Total Cost of Revenue		 2.80 3.33 3.64 2.04 0.05 0.09 0.06 0.01 0.01 0.00 0.00
Operating Cost of Revenue		 2.80 3.33 3.64 2.04 0.05 0.09 0.06 0.01 0.01 0.00 0.00
Total Operating Expenses		 18 21 28 28 28 24 26 12 16 14 14
Selling, General & Admin Expense		 6.64 7.01 7.70 5.54 7.68 5.13 5.80 3.73 7.03 4.72 4.92
Research & Development Expense		 12 14 20 22 21 18 21 8.75 9.12 9.15 9.30
Restructuring Charge		 - 0.00 0.00 - 0.00 1.32 0.00 - 0.00 0.00 0.00
Total Other Income / (Expense), net		 3.51 3.86 -5.50 17 -0.12 -3.38 5.29 0.69 0.78 1.60 1.80
Interest Expense		 -2.50 -2.73 -4.49 -4.02 -2.68 -2.37 -2.58 0.17 -0.69 -0.78 -0.70
Other Income / (Expense), net		 1.02 1.13 -9.98 13 -2.80 -5.75 2.70 0.86 0.09 0.82 1.10
Income Tax Expense		 0.24 0.23 0.05 0.32 0.00 0.01 0.00 - 0.00 0.00 0.00
Basic Earnings per Share		 ($0.02) ($0.14) ($0.25) $0.08 ($0.20) ($0.19) ($0.15) ($0.09) ($0.11) ($0.09) ($0.08)
Weighted Average Basic Shares Outstanding		 131.88M 140.21M 141.20M 138.75M 141.68M 141.70M 141.70M 141.69M 141.70M 141.71M 165.60M
Diluted Earnings per Share		 ($0.02) ($0.14) ($0.25) $0.08 ($0.20) ($0.19) ($0.15) ($0.09) ($0.11) ($0.09) ($0.08)
Weighted Average Diluted Shares Outstanding		 131.88M 140.21M 141.20M 138.75M 141.68M 141.70M 141.70M 141.69M 141.70M 141.71M 165.60M
Weighted Average Basic & Diluted Shares Outstanding		 - - - 141.67M 141.69M 141.70M 141.70M 141.70M 141.70M 141.74M 186.61M

Annual Cash Flow Statements for Silence Therapeutics

This table details how cash moves in and out of Silence Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -27 13 24 62 -25 1.77 52 -110
Net Cash From Operating Activities		 -21 5.60 3.20 64 -57 -49 -68 -62
Net Cash From Continuing Operating Activities		 -22 5.60 3.20 64 -57 -49 -68 -62
Net Income / (Loss) Continuing Operations		 -26 0.00 0.00 0.00 -50 -54 -45 -89
Consolidated Net Income / (Loss)		 -26 - - - -50 -54 -45 -89
Depreciation Expense		 0.48 0.60 0.65 - 0.38 0.37 0.34 0.31
Amortization Expense		 0.00 - 0.03 - 0.22 0.25 0.26 0.24
Non-Cash Adjustments To Reconcile Net Income		 0.88 0.96 2.53 51 1.58 15 6.92 20
Changes in Operating Assets and Liabilities, net		 2.34 4.05 - 14 -8.89 -11 -30 6.13
Net Cash From Investing Activities		 -6.15 -0.01 0.00 -1.77 -20 19 -22 -48
Net Cash From Continuing Investing Activities		 0.17 -0.01 0.00 -1.77 -20 19 -22 -48
Purchase of Property, Plant & Equipment		 -0.17 -0.01 - -1.77 -0.17 -0.06 -0.21 -0.06
Acquisitions		 - - - - -0.37 0.00 0.00 0.00
Other Investing Activities, net		 - - - - -20 19 -22 -48
Net Cash From Financing Activities		 0.43 6.99 21 0.00 53 32 142 0.02
Net Cash From Continuing Financing Activities		 0.43 6.99 21 0.00 53 32 142 0.02
Issuance of Common Equity		 0.43 6.99 - - 53 32 142 0.02
Other Net Changes in Cash		 - - - -0.14 - - 0.06 0.20
Cash Income Taxes Paid		 - - - - 0.00 -0.80 0.43 0.64

Quarterly Cash Flow Statements for Silence Therapeutics

This table details how cash moves in and out of Silence Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents		 74 -4.26 -56 39 -57 -23 40 -71 -5.60 66 176
Net Cash From Operating Activities		 -9.14 -5.41 -26 -27 -12 -22 -11 -17 -16 1.52 -13
Net Cash From Continuing Operating Activities		 -9.14 -5.41 -26 -27 -12 -22 -11 -17 -16 1.52 -13
Net Income / (Loss) Continuing Operations		 -2.31 -20 -36 12 -29 -27 -21 -12 -15 -12 -12
Consolidated Net Income / (Loss)		 -2.31 -20 -36 12 -29 -27 -21 -12 -15 -12 -12
Depreciation Expense		 0.09 0.09 0.09 0.08 0.07 0.08 0.08 0.08 0.07 0.07 0.07
Amortization Expense		 0.06 0.06 0.07 0.06 0.07 0.07 0.08 0.04 0.03 0.04 0.03
Non-Cash Adjustments To Reconcile Net Income		 12 0.29 8.34 -14 14 7.92 -1.65 -0.55 1.69 14 0.02
Changes in Operating Assets and Liabilities, net		 -19 14 1.45 -26 2.15 -2.50 12 -5.08 -2.45 -0.15 -0.47
Net Cash From Financing Activities		 133 1.19 7.97 -0.10 0.01 0.00 - - 0.00 0.00 188
Net Cash From Continuing Financing Activities		 133 1.19 7.97 -0.10 0.01 0.00 - - 0.00 0.00 188
Issuance of Common Equity		 133 1.19 7.97 -0.10 0.01 0.00 - - 0.00 0.00 188
Other Net Changes in Cash		 -0.04 -0.01 - - 0.23 0.20 -0.11 -0.13 -0.02 -0.06 0.05
Cash Income Taxes Paid		 -0.11 -0.11 -0.11 0.76 -0.08 -0.43 -0.12 1.27 -0.09 -0.08 -0.89

Annual Balance Sheets for Silence Therapeutics

This table presents Silence Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 56 88 117 130 130 119 203 131
Total Current Assets		 38 50 104 117 117 103 187 119
Cash & Equivalents		 27 18 37 99 66 69 121 11
Short-Term Investments		 13 53 16 0.00 20 0.00 26 74
Accounts Receivable		 0.00 0.01 40 0.45 1.11 0.29 0.97 0.00
Other Current Assets		 1.12 1.17 6.30 7.45 12 34 39 34
Plant, Property, & Equipment, net		 1.17 0.81 1.54 2.62 2.66 1.94 1.82 1.58
Total Noncurrent Assets		 11 11 12 11 10 14 13 11
Goodwill		 10 10 11 10 9.67 9.98 9.39 11
Intangible Assets		 0.08 0.05 0.02 0.03 0.39 0.36 0.31 0.29
Other Noncurrent Operating Assets		 - - - - 0.00 4.02 3.75 0.29
Total Liabilities & Shareholders' Equity		 50 61 117 130 130 119 203 131
Total Liabilities		 4.88 33 105 118 103 97 69 69
Total Current Liabilities		 4.88 13 35 20 27 22 17 14
Accounts Payable		 4.88 9.13 11 15 15 16 16 13
Other Current Liabilities		 0.00 3.66 24 5.92 11 6.80 0.42 0.26
Total Noncurrent Liabilities		 0.00 21 70 98 77 75 52 56
Other Noncurrent Operating Liabilities		 0.00 21 70 98 77 75 52 56
Commitments & Contingencies		 - - - - - 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 45 28 12 12 27 22 134 62
Total Preferred & Common Equity		 45 28 12 12 27 22 134 62
Total Common Equity		 45 28 12 12 27 22 134 62
Common Stock		 4.53 5.19 5.69 6.06 6.51 465 620 628
Retained Earnings		 -170 -201 -252 -301 -318 -432 -474 -563
Accumulated Other Comprehensive Income / (Loss)		 - - - - - -11 -12 -2.98

Quarterly Balance Sheets for Silence Therapeutics

This table presents Silence Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets		 185 165 147 115 106 281
Total Current Assets		 170 149 134 103 94 270
Cash & Equivalents		 65 42 82 5.66 72 248
Short-Term Investments		 72 72 20 64 0.00 0.00
Accounts Receivable		 0.04 0.09 0.03 0.00 0.00 0.00
Other Current Assets		 33 34 31 33 22 22
Plant, Property, & Equipment, net		 1.69 1.78 1.66 1.40 1.33 1.22
Total Noncurrent Assets		 14 15 12 11 11 11
Goodwill		 9.78 11 11 10 10 10
Intangible Assets		 0.31 0.32 0.30 0.25 0.24 0.23
Other Noncurrent Operating Assets		 3.72 3.97 0.59 0.27 0.24 0.22
Total Liabilities & Shareholders' Equity		 185 165 147 115 106 281
Total Liabilities		 73 71 73 66 68 66
Total Current Liabilities		 19 15 17 10 13 11
Accounts Payable		 19 14 17 10 13 11
Other Current Liabilities		 0.45 0.46 0.39 0.09 0.10 0.09
Total Noncurrent Liabilities		 53 56 55 55 55 55
Other Noncurrent Operating Liabilities		 53 56 55 55 55 55
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 113 94 74 49 38 215
Total Preferred & Common Equity		 113 94 74 49 38 215
Total Common Equity		 113 94 74 49 38 215
Common Stock		 623 625 628 630 631 820
Retained Earnings		 -503 -530 -551 -578 -590 -602
Accumulated Other Comprehensive Income / (Loss)		 -8.08 -1.40 -3.07 -3.37 -3.34 -3.48

Annual Metrics And Ratios for Silence Therapeutics

This table displays calculated financial ratios and metrics derived from Silence Therapeutics' official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 83,306,259.00 89,784,720.00 107,808,471.00 118,846,966.00 - 141,701,848.00
DEI Adjusted Shares Outstanding		 0.00 0.00 83,306,259.00 89,784,720.00 107,808,471.00 118,846,966.00 - 141,701,848.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -0.53 -0.59 -0.47 -0.46 - -0.63
Growth Metrics		 - - - - - - - -
Revenue Growth		 0.00% 0.00% 2,214.34% 123.99% 29.20% 46.12% 36.71% -98.71%
EBITDA Growth		 0.00% -14.81% -63.52% -28.11% 4.82% -9.73% 10.82% -65.79%
EBIT Growth		 0.00% -14.98% -62.52% -26.33% 3.85% -9.68% 10.76% -65.06%
NOPAT Growth		 0.00% -14.98% -62.52% -26.33% 1.31% -5.48% 1.65% -43.84%
Net Income Growth		 0.00% -10.63% -71.31% -19.69% 5.39% -7.74% 16.45% -95.57%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 5.77% 32.65% -90.91%
Operating Cash Flow Growth		 0.00% 126.24% -42.84% 1,902.03% -188.97% 13.29% -36.75% 7.94%
Free Cash Flow Firm Growth		 0.00% 0.00% -256.00% 136.11% -2,051.59% 18.81% -34.43% 30.27%
Invested Capital Growth		 0.00% -262.55% -141.50% -113.88% 32.40% 21.49% 71.56% -71.36%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -97.84%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -26.87%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -26.63%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -9.77%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -37.30%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -36.96%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 14.07%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 18.91%
Profitability Metrics		 - - - - - - - -
Gross Margin		 0.00% 100.00% 31.34% 39.94% 37.83% 59.34% 72.70% 61.54%
EBITDA Margin		 0.00% -9,131.95% -645.21% -369.02% -271.85% -204.15% -133.17% -17,085.69%
Operating Margin		 0.00% -9,317.20% -654.26% -369.02% -281.87% -203.47% -146.38% -16,292.84%
EBIT Margin		 0.00% -9,317.20% -654.26% -369.02% -274.61% -206.12% -134.54% -17,184.97%
Profit (Net Income) Margin		 0.00% -8,025.40% -594.03% -317.44% -232.44% -171.37% -104.74% -15,851.88%
Tax Burden Percent		 89.70% 85.62% 90.31% 85.94% 101.39% 101.79% 101.90% 100.01%
Interest Burden Percent		 99.81% 100.60% 100.54% 100.09% 83.49% 81.68% 76.40% 92.23%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -52.52% -71.71% -221.82% -445.55% -263.76% -222.93% -58.08% -90.27%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% -41.98% -47.77% -50.02% -45.80% -52.33% -36.14% -57.51%
Return on Assets (ROA)		 0.00% -36.16% -43.37% -43.03% -38.76% -43.51% -28.14% -53.05%
Return on Common Equity (ROCE)		 -52.52% -71.71% -221.82% -445.55% -263.76% -222.93% -58.08% -90.27%
Return on Equity Simple (ROE_SIMPLE)		 -52.52% -93.65% -359.28% -462.23% -188.83% -246.57% -33.81% 0.00%
Net Operating Profit after Tax (NOPAT)		 -18 -21 -34 -43 -43 -45 -44 -64
NOPAT Margin		 0.00% -6,522.04% -457.98% -258.31% -197.31% -142.43% -102.46% -11,404.99%
Net Nonoperating Expense Percent (NNEP)		 -14.98% -12.32% -20.70% -12.93% -8.18% -11.82% -0.91% -21.39%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -160.29% -204.92% -33.07% -102.33%
Cost of Revenue to Revenue		 0.00% 0.00% 68.66% 60.06% 62.17% 40.66% 27.30% 38.46%
SG&A Expenses to Revenue		 0.00% 3,951.63% 255.21% 161.16% 118.60% 82.87% 62.15% 3,997.14%
R&D to Revenue		 0.00% 5,465.57% 368.84% 247.81% 201.11% 179.94% 156.93% 12,120.39%
Operating Expenses to Revenue		 0.00% 9,417.20% 685.60% 408.96% 319.70% 262.80% 219.07% 16,354.38%
Earnings before Interest and Taxes (EBIT)		 -26 -30 -49 -62 -59 -65 -58 -96
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -26 -30 -48 -62 -59 -65 -58 -96
Valuation Ratios		 - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 57.64 17.12 28.38 2.03 4.61
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 540.00 27.50 53.58 2.19 5.59
Price to Revenue (P/Rev)		 0.00 0.00 0.00 39.58 21.08 19.73 6.30 513.74
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 33.63 17.09 17.55 2.89 361.48
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 8.79 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 154.31 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.76 -1.09 -2.45 -6.42 -4.87 -3.19 -1.39 -1.18
Leverage Ratio		 1.25 1.98 5.11 10.35 6.80 5.12 2.06 1.70
Compound Leverage Factor		 1.25 2.00 5.14 10.36 5.68 4.19 1.58 1.57
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 0.00 0.00 -0.44 -1.28 -1.94 -0.62 -4.95
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - -
Current Ratio		 7.70 3.88 2.99 5.69 4.41 4.62 11.14 8.72
Quick Ratio		 8.25 5.54 2.67 4.87 3.28 3.09 8.82 6.25
Cash Flow Metrics		 - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 6.48 -10 3.65 -71 -58 -78 -54
Operating Cash Flow to CapEx		 -12,892.34% 46,976.68% 0.00% 3,622.73% -32,973.41% -88,325.00% -32,056.87% -113,220.00%
Free Cash Flow to Firm to Interest Expense		 0.00 30.02 -22.93 52.04 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 25.94 7.26 913.35 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 25.88 7.26 888.13 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - -
Asset Turnover		 0.00 0.00 0.07 0.14 0.17 0.25 0.27 0.00
Accounts Receivable Turnover		 0.00 0.00 0.37 0.83 27.91 45.36 68.55 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.33 6.37 8.05 8.20 13.77 23.03 0.33
Accounts Payable Turnover		 0.00 0.00 0.51 0.78 0.90 0.84 0.74 0.01
Days Sales Outstanding (DSO)		 0.00 0.00 976.28 440.68 13.08 8.05 5.32 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 721.61 466.78 404.15 436.77 493.51 25,257.15
Cash Conversion Cycle (CCC)		 0.00 0.00 254.67 -26.11 -391.07 -428.72 -488.18 -25,257.15
Capital & Investment Metrics		 - - - - - - - -
Invested Capital		 11 -17 -41 -88 -60 -47 -13 -23
Invested Capital Turnover		 0.00 -0.10 -0.26 -0.26 -0.29 -0.59 -1.44 -0.03
Increase / (Decrease) in Invested Capital		 0.00 -28 -24 -47 29 13 33 -9.50
Enterprise Value (EV)		 0.00 0.00 0.00 564 370 555 125 202
Market Capitalization		 0.00 0.00 0.00 663 456 624 273 287
Book Value per Share		 $0.00 $0.00 $0.15 $0.14 $0.30 $0.20 $1.13 $0.44
Tangible Book Value per Share		 $0.00 $0.00 $0.02 $0.01 $0.18 $0.11 $1.05 $0.36
Total Capital		 45 28 12 12 27 22 134 62
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -41 -71 -54 -100 -86 -69 -147 -85
Capital Expenditures (CapEx)		 0.17 0.01 0.00 1.77 0.17 0.06 0.21 0.06
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -7.53 -34 16 -3.20 4.35 12 23 20
Debt-free Net Working Capital (DFNWC)		 33 37 69 96 90 81 171 105
Net Working Capital (NWC)		 33 37 69 96 90 81 171 105
Net Nonoperating Expense (NNE)		 5.12 4.86 10 9.91 7.61 9.16 0.99 25
Net Nonoperating Obligations (NNO)		 -34 -45 -54 -100 -86 -69 -147 -85
Total Depreciation and Amortization (D&A)		 0.48 0.60 0.68 0.00 0.60 0.62 0.59 0.56
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -10,534.82% 216.88% -19.10% 20.07% 38.01% 53.65% 3,565.47%
Debt-free Net Working Capital to Revenue		 0.00% 11,398.34% 927.61% 573.23% 416.84% 255.40% 394.25% 18,791.59%
Net Working Capital to Revenue		 0.00% 11,398.34% 927.61% 573.23% 416.84% 255.40% 394.25% 18,791.59%
Earnings Adjustments		 - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($0.40) $0.00 $0.00 $0.00 ($0.33) ($0.63)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 83.31M 89.78M 107.81M 118.85M 138.75M 141.69M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($0.40) $0.00 $0.00 $0.00 ($0.33) ($0.63)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 83.31M 89.78M 107.81M 118.85M 138.75M 141.69M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($0.40) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 83.31M 89.78M 107.81M 118.85M 141.67M 141.70M
Normalized Net Operating Profit after Tax (NOPAT)		 -18 -21 -34 -43 -43 -45 -44 -63
Normalized NOPAT Margin		 0.00% -6,522.04% -457.98% -258.31% -197.31% -142.43% -102.46% -11,239.20%
Pre Tax Income Margin		 0.00% -9,372.94% -657.80% -369.36% -229.26% -168.35% -102.79% -15,849.91%
Debt Service Ratios		 - - - - - - - -
EBIT to Interest Expense		 0.00 -139.47 -110.98 -881.04 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 -97.63 -77.69 -616.73 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 -139.53 -110.98 -906.25 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 -97.69 -77.69 -641.94 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Silence Therapeutics

This table displays calculated financial ratios and metrics derived from Silence Therapeutics' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding		 118,846,966.00 118,846,966.00 118,846,966.00 118,846,966.00 141,674,074.00 141,690,850.00 141,701,848.00 141,701,848.00 141,701,848.00 141,703,840.00 186,609,073.00
DEI Adjusted Shares Outstanding		 118,846,966.00 118,846,966.00 118,846,966.00 118,846,966.00 141,674,074.00 141,690,850.00 141,701,848.00 141,701,848.00 141,701,848.00 141,703,840.00 186,609,073.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.02 -0.17 -0.30 0.10 -0.20 -0.19 -0.15 -0.08 -0.11 -0.09 -0.07
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% -99.10% -70.37% -89.39% -99.87% 197.18% -100.00% -100.00%
EBITDA Growth		 0.00% 0.00% 0.00% 0.00% -604.40% -33.73% 41.29% -231.40% 49.98% 56.25% 44.33%
EBIT Growth		 0.00% 0.00% 0.00% 0.00% -583.96% -33.50% 41.12% -234.85% 49.86% 56.10% 44.25%
NOPAT Growth		 0.00% 0.00% 0.00% 0.00% -409.03% -2.46% 12.51% -105.66% 44.61% 42.14% 45.80%
Net Income Growth		 0.00% 0.00% 0.00% 0.00% -1,134.00% -38.47% 41.04% -195.68% 47.57% 55.15% 40.71%
EPS Growth		 0.00% 0.00% 0.00% 0.00% -900.00% -35.71% 40.00% -212.50% 45.00% 52.63% 46.67%
Operating Cash Flow Growth		 0.00% 0.00% 0.00% 0.00% -34.63% -302.74% 57.47% 37.09% -26.76% 106.97% -17.31%
Free Cash Flow Firm Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -461.89% 20.20% -155.83%
Invested Capital Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -71.36% 13.09% -67.92% -16.03%
Revenue Q/Q Growth		 0.00% -95.18% 98.15% 1,589.25% -99.44% 57.75% -29.02% -78.62% 1,141.18% -100.00% 0.00%
EBITDA Q/Q Growth		 0.00% -401.22% -80.15% 121.95% -455.42% 4.84% 20.91% 50.88% -35.30% 16.76% -0.62%
EBIT Q/Q Growth		 0.00% -387.82% -79.62% 121.52% -462.81% 4.79% 20.78% 50.72% -34.90% 16.63% -0.60%
NOPAT Q/Q Growth		 0.00% -319.06% -28.26% 79.80% -368.87% 15.65% -9.52% 52.52% -26.29% 11.90% -2.59%
Net Income Q/Q Growth		 0.00% -754.46% -79.92% 134.61% -331.91% 4.12% 23.38% 43.84% -27.08% 17.98% -1.29%
EPS Q/Q Growth		 0.00% -600.00% -78.57% 132.00% -350.00% 5.00% 21.05% 40.00% -22.22% 18.18% 11.11%
Operating Cash Flow Q/Q Growth		 0.00% 40.84% -373.41% -7.32% 55.21% -76.98% 50.00% -58.73% 9.74% 109.73% -941.63%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -17.38% 202.50% -92.04% -1,920.29% 127.44% -240.50%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -78.73% 15.93% -40.65% 18.91% 9.36% -62.43% 2.81%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 82.16% -340.87% -142.92% 91.95% 61.97% 62.05% 59.75% 64.71% 97.39% 0.00% 0.00%
EBITDA Margin		 -28.10% -2,924.47% -2,658.88% 34.55% -21,880.99% -13,199.55% -14,706.92% -33,785.29% -3,682.94% 0.00% 0.00%
Operating Margin		 -35.55% -3,093.65% -2,002.47% -17.20% -20,006.34% -10,697.77% -16,505.66% -36,650.00% -3,729.15% 0.00% 0.00%
EBIT Margin		 -29.07% -2,944.31% -2,668.96% 33.99% -21,978.17% -13,265.63% -14,805.03% -34,117.65% -3,708.06% 0.00% 0.00%
Profit (Net Income) Margin		 -14.73% -2,613.10% -2,372.76% 48.61% -20,091.55% -12,211.61% -13,181.13% -34,617.65% -3,544.31% 0.00% 0.00%
Tax Burden Percent		 111.80% 101.17% 100.14% 97.43% 100.00% 100.04% 100.00% 100.00% 100.00% 100.01% 100.00%
Interest Burden Percent		 45.32% 87.73% 88.78% 146.78% 91.42% 92.02% 89.03% 101.47% 95.58% 94.04% 94.69%
Effective Tax Rate		 0.00% 0.00% 0.00% 2.57% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% 0.00% 0.00% -58.08% -63.44% -84.04% -87.14% -90.27% -92.56% -90.41% -35.58%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 9.13% -3,285.61% -2,181.25% -2,605.18% -114.18% -20.71% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 13.06% -3,003.57% -2,007.94% -2,319.43% -115.85% -19.80% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% 0.00% 0.00% -58.08% -63.44% -84.04% -87.14% -90.27% -92.56% -90.41% -35.58%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -3.91 -16 -21 -4.24 -20 -17 -18 -8.72 -11 -9.71 -9.96
NOPAT Margin		 -24.89% -2,165.56% -1,401.73% -16.76% -14,004.44% -7,488.44% -11,553.96% -25,655.00% -2,610.40% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% 0.00% 0.00% 11.23% -12.66% -18.54% -5.06% -2.62% -3.82% -2.75% -1.41%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -3.16% -17.64% -17.82% -24.80% -14.00% -22.30% -25.23% -4.63%
Cost of Revenue to Revenue		 17.84% 440.87% 242.92% 8.05% 38.03% 37.95% 40.25% 35.29% 2.61% 0.00% 0.00%
SG&A Expenses to Revenue		 42.26% 927.12% 513.82% 21.90% 5,411.27% 2,290.63% 3,644.65% 10,982.35% 1,664.93% 0.00% 0.00%
R&D to Revenue		 75.45% 1,825.66% 1,345.73% 87.24% 14,657.04% 7,878.13% 12,920.75% 25,732.35% 2,161.61% 0.00% 0.00%
Operating Expenses to Revenue		 117.71% 2,752.78% 1,859.55% 109.15% 20,068.31% 10,759.82% 16,565.41% 36,714.71% 3,826.54% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -4.56 -22 -40 8.60 -31 -30 -24 -12 -16 -13 -13
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -4.41 -22 -40 8.74 -31 -30 -23 -11 -16 -13 -13
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 2.03 1.18 2.91 3.31 4.61 5.04 13.48 2.40
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 2.19 1.30 3.29 3.88 5.59 6.42 18.58 2.52
Price to Revenue (P/Rev)		 0.00 0.00 0.00 6.30 4.81 10.08 9.49 513.74 296.69 843.31 1,132.47
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 2.89 0.00 5.88 5.53 361.48 213.16 726.15 589.36
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 0.00 0.00 -1.10 -1.21 -1.21 -1.38 -1.18 -1.27 -1.40 -1.21
Leverage Ratio		 0.00 0.00 0.00 2.06 1.64 1.75 1.98 1.70 1.85 2.05 1.48
Compound Leverage Factor		 0.00 0.00 0.00 3.03 1.50 1.61 1.76 1.73 1.77 1.93 1.40
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 0.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 0.00 0.00 0.47 -2.13 -1.63 -2.63 -2.83 -4.23 -2.66 2.62
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.00 0.00 0.00 11.14 8.81 10.06 7.69 8.72 9.83 7.42 23.94
Quick Ratio		 0.00 0.00 0.00 8.82 7.09 7.74 5.88 6.25 6.70 5.67 22.00
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 0.00 0.00 0.00 3.90 3.23 9.76 0.78 -14 3.88 -5.45
Operating Cash Flow to CapEx		 0.00% -6,363.53% -40,010.94% -44,324.19% -307,725.00% -45,383.33% -363,033.33% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.57 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -101.69 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -101.69 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.27 0.15 0.16 0.18 0.00 0.01 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 68.55 675.63 319.64 922.50 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 23.03 16.36 15.31 15.61 0.33 0.54 0.40 0.32
Accounts Payable Turnover		 0.00 0.00 0.00 0.74 0.48 0.41 0.13 0.01 0.01 0.01 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 5.32 0.54 1.14 0.40 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 493.51 757.54 898.13 2,767.71 25,257.15 30,960.28 56,474.31 223,483.15
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 -488.18 -757.00 -896.99 -2,767.32 -25,257.15 -30,960.28 -56,474.31 -223,483.15
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.00 0.00 0.00 -13 -24 -20 -28 -23 -21 -34 -33
Invested Capital Turnover		 0.00 0.00 0.00 -3.25 -2.33 -2.72 -1.84 -0.03 -0.04 -0.02 -0.02
Increase / (Decrease) in Invested Capital		 0.00 0.00 0.00 0.00 -24 -20 -28 -9.50 3.12 -14 -4.51
Enterprise Value (EV)		 0.00 0.00 0.00 125 -3.36 160 143 202 179 447 269
Market Capitalization		 856 753 720 273 133 274 245 287 249 519 516
Book Value per Share		 $0.00 $0.00 $0.00 $1.13 $0.80 $0.66 $0.52 $0.44 $0.35 $0.27 $1.52
Tangible Book Value per Share		 $0.00 $0.00 $0.00 $1.05 $0.72 $0.59 $0.45 $0.36 $0.27 $0.20 $1.44
Total Capital		 0.00 0.00 0.00 134 113 94 74 62 49 38 215
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 0.00 0.00 -147 -137 -114 -102 -85 -70 -72 -248
Capital Expenditures (CapEx)		 0.00 0.09 0.06 0.06 0.00 0.05 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 0.00 0.00 23 14 20 14 20 22 9.51 11
Debt-free Net Working Capital (DFNWC)		 0.00 0.00 0.00 171 151 134 116 105 92 82 258
Net Working Capital (NWC)		 0.00 0.00 0.00 171 151 134 116 105 92 82 258
Net Nonoperating Expense (NNE)		 -1.59 3.38 15 -17 8.64 11 2.59 3.05 3.94 2.56 2.47
Net Nonoperating Obligations (NNO)		 0.00 0.00 0.00 -147 -137 -114 -102 -85 -70 -72 -248
Total Depreciation and Amortization (D&A)		 0.15 0.15 0.15 0.14 0.14 0.15 0.16 0.11 0.11 0.11 0.11
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 53.65% 50.51% 72.25% 54.44% 3,565.47% 2,659.59% 1,546.83% 2,337.28%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 394.25% 543.40% 492.42% 450.07% 18,791.59% 11,012.16% 13,262.93% 56,648.46%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 394.25% 543.40% 492.42% 450.07% 18,791.59% 11,012.16% 13,262.93% 56,648.46%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 $0.08 ($0.20) ($0.19) ($0.15) ($0.09) ($0.11) ($0.09) ($0.08)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 0.00 138.75M 141.68M 141.70M 141.70M 141.69M 141.70M 141.71M 165.60M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.08 ($0.20) ($0.19) ($0.15) ($0.09) ($0.11) ($0.09) ($0.08)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 0.00 138.75M 141.68M 141.70M 141.70M 141.69M 141.70M 141.71M 165.60M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 141.67M 141.69M 141.70M 141.70M 141.70M 141.70M 141.74M 186.61M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.91 -16 -21 -4.24 -20 -16 -18 -8.72 -11 -9.71 -9.96
Normalized NOPAT Margin		 -24.89% -2,165.56% -1,401.73% -16.76% -14,004.44% -7,074.69% -11,553.96% -25,655.00% -2,610.40% 0.00% 0.00%
Pre Tax Income Margin		 -13.17% -2,582.94% -2,369.49% 49.90% -20,091.55% -12,207.14% -13,180.50% -34,617.65% -3,544.31% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -68.24 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -51.31 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -68.24 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -51.31 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Silence Therapeutics’ Q2 2026 results show some sequential improvement, but the company remains an early-stage biotechnology business with no meaningful recurring revenue and continued net losses. Revenue fell to zero from $422,000 in Q1 2026, while the net loss improved to $12.3 million from $15.0 million. The improvement was helped by lower selling, general and administrative expenses and higher other income, rather than by operating growth.

  • Quarterly net loss narrowed: Q2 2026 net loss was $12.3 million, compared with $15.0 million in Q1 2026, $11.8 million in Q4 2025, and $21.0 million in Q3 2025. The loss also improved substantially from the $27.4 million restated loss in Q2 2025.
  • Operating expenses decreased sequentially: Total operating expenses declined to $13.9 million from $16.1 million in Q1 2026. SG&A fell to $4.7 million from $7.0 million, while research and development spending remained relatively stable at $9.1 million.
  • Liquidity remains adequate in the near term: Cash and equivalents totaled $72.1 million at June 30, 2026. Including no short-term investments, current assets were $94.3 million versus current liabilities of $12.7 million, providing a current ratio of roughly 7.4.
  • Operating cash flow turned positive in Q2: The company reported $1.5 million of operating cash flow, compared with negative $15.6 million in Q1. However, this result included $13.8 million of non-cash adjustments and should not be viewed as evidence of sustainable cash generation yet.
  • Investment activity drove the cash increase: Q2 investing activities provided $64.9 million, and cash increased by $66.5 million during the quarter. This appears primarily related to the movement or liquidation of investments rather than business-generated cash flow; short-term investments declined from $64.4 million in Q1 to zero in Q2.
  • Revenue remains highly inconsistent: Quarterly revenue was $25.3 million in Q4 2024 but dropped to $224,000 in Q2 2025, $34,000 in Q4 2025, $422,000 in Q1 2026 and zero in Q2 2026. This volatility makes revenue-based valuation and forecasting difficult.
  • The company is still far from profitability: Q2 generated no revenue against $13.9 million of operating expenses, producing an operating loss of $13.9 million. Research and development spending alone was more than 20 times Q2 revenue on an annualized comparison.
  • Cash resources have declined over the broader period: Cash and short-term investments totaled approximately $72.1 million at June 30, 2026, down from $114.2 million at June 30, 2025 and $136.3 million at March 31, 2025. Continued operating losses could accelerate the need for additional funding.
  • Retained earnings remain deeply negative: Retained earnings stood at negative $589.6 million, reflecting the company’s long history of accumulated losses. Total shareholders’ equity fell to $38.5 million from $49.4 million in Q1 2026 and $74.1 million in Q3 2025.
  • Shareholder dilution remains a risk: Weighted-average shares outstanding increased from 131.9 million in Q1 2024 to 141.7 million in Q2 2026. Although Q2 financing proceeds were minimal, future equity offerings could be needed to fund development and could reduce existing shareholders’ ownership percentage.

Overall, the latest quarter offers modest positives through lower expenses, a smaller net loss and substantial short-term liquidity. However, the absence of revenue, persistent operating losses and declining cash and equity levels remain the central risks for SLN investors.

11/15/26 03:24 AM ETAI Generated. May Contain Errors.

Silence Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Silence Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Silence Therapeutics' net income appears to be on a downward trend, with a most recent value of -$88.61 million in 2025, falling from -$23.46 million in 2018. The previous period was -$45.31 million in 2024. Find out what analysts predict for Silence Therapeutics in the coming months.

Silence Therapeutics' total operating income in 2025 was -$91.08 million, based on the following breakdown:
  • Total Gross Profit: $344 thousand
  • Total Operating Expenses: $91.42 million

Over the last 7 years, Silence Therapeutics' total revenue changed from $0.00 in 2018 to $559 thousand in 2025, a change of 55,900,000.0%.

In the past 6 quarters, Silence Therapeutics' cash and equivalents has ranged from $5.66 million in Q1 2026 to $247.66 million in Q3 2026, and is currently $247.66 million as of their latest financial filing in Q3 2026.

Silence Therapeutics had total debt of $0.00 at the end of 2025, compared with none in 2024, and none in 2018.

Over the last 7 years, Silence Therapeutics' book value per share changed from 0.00 in 2018 to 0.44 in 2025, a change of 44.0%.


Related Companies

Financial statements for NASDAQ:SLN last updated on 11/13/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Uranium Mine Flood That Sparked a 2006 Price Surge Returns
In 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...
Digest Publishing | Sponsoredtc pixel
Unbelievable…Congress is About to Do What?
Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washing...
Paradigm Press | Sponsoredtc pixel
Last note from me on this
Joel Peterson's free workshop breaks down a three step, three color system that works across stocks, ETFs, gol...
The Cycle Code | Sponsoredtc pixel
Elon wants to move AI off the planet. Amazon isn't ready.
What if the next AI race isn't on Earth? Tim Bohen's Mission X presentation explores Elon Musk's idea of movin...
StocksToTrade | Sponsoredtc pixel